Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study
Objective To investigate the risk of cardiovascular events associated with commonly used dual and triple therapies of evogliptin, a recently introduced dipeptidyl peptidase-4 inhibitor (DPP4i), for managing type 2 diabetes in routine clinical practice.Design A retrospective cohort study.Setting Kore...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-04-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/4/e077084.full |